This invention pertains to the identification of two novel epithelial signaling pathways in ER-positive breast cancer s and the discovery that the cellular biology and (likely also the clinical outcome) of ER-positive breast cancer cells is unexpectedly altered when these signaling pathways are activated. The first pathway pertains to the discovery that NF-κB activation and/or DNA binding is implicated in the etiology of ER-positive breast (and other) cancers. The second pathway involves ligand-independent quinine-mediated ER activation by posphorylation (e.g. on SER-118 and SER-167 residues of ER) and nuclear translocation of full-length (67 kDA) ER as well as the phorphorylating activation of a truncated and nuclear-localized ER variant (˜52 kDa).
本发明涉及在ER阳性乳腺癌中发现两种新型上皮信号通路,并发现当这些信号通路被激活时,ER阳性乳腺癌细胞的细胞
生物学特性和(可能还有临床结果)会发生意想不到的改变。第一条途径是发现 NF-κB 激活和/或 DNA 结合与 ER 阳性乳腺癌(和其他癌症)的病因有关。第二种途径涉及与
配体无关的
奎宁介导的ER激活,即ER的正理论化(如ER的
SER-118和
SER-167残基)和全长(67 k
DA)ER的核转位,以及截短的核定位ER变体(˜52 k
DA)的正理论化激活。